NEWARK, Del., Aug. 22 Strategic Diagnostics Inc.(Nasdaq: SDIX) -- a leading provider of biotechnology-based detectionsolutions for a broad range of food, water, agricultural, environmental andlife science applications, announced today that due to a change in theconference agenda, SDI's presentation at the Roth Capital Partner's Roth 2007New York Conference at the Westin Hotel in Manhattan is now scheduled for3 p.m. on Sept 5, 2007 in the Majestic II (Track 1) room.
The presentation will be webcast athttp://www.wsw.com/webcast/roth13/sdix/ for approximately 30 days followingthe conclusion of the presentation. Following the presentation, Mr. Knightwill attend a breakout session. One-on-one meetings may be scheduled throughRoth Capital Partners by calling (949) 720-5700.
Each presentation is designed to provide analysts, institutional brokersand portfolio managers with an overview of the Company's expertise in theproduction of antibodies, used both in diagnostic tests and provided to theproteomics, pharmaceutical, diagnostics and biomedical research industries toenable rapid discovery and commercialization of products. StrategicDiagnostics is a leader in the food pathogen industry, providingcomprehensive, accurate, and easy-to-use tests including the recentlyintroduced RapidChek(R) SELECT(TM) Salmonella product. The Company is also anemerging leader in producing monoclonal and polyclonal antibodies for thepharmaceutical and research industries. The Company's patent-pendingtechnology also addresses renewable energy opportunities and can be used toincrease efficiency in the production of ethanol. Management will discuss therecurring revenue component of the Company's business model, revenue potentialfrom new product and services, and the Company's strategy for sustainablegrowth.
About the Roth Capital Partners and the 2007 New York Conference
Roth is one of the last remaining independent full-service investmentbanks dedicated to the small and micro-cap market. The firm is privately ownedwith current principals being majority owners. The core management team hasbeen consistent for many years. Since the inception of the firm in 1984, Rothhas been a leader and innovator in the small and micro cap markets. Roth'sexclusive focus has been, is, and will continue to offer a full spectrum ofinvestment banking services, including raising capital, research coverage,trading and market making, merger and acquisition advisory services, andinvestor conferences. Roth's award-winning research is the foundation of itsfirm and key to its understanding of the micro-and small- cap sector. Thisresearch, when combined with a seasoned institutional sales team and itshighly visible investor conferences, creates an unparalleled institutionalsponsorship platform for growth companies. Roth has raised more than $10billion for small and micro cap public companies and completed over 135merger, acquisition and advisory assignments. Since year 2000, Roth has been aleading placement agent for the number of PIPE transactions, raising over $2billion for its clients. Roth received top 20 IPO aftermarket performancerankings for six consecutive years from 1994 to 1999. The 5th Annual New YorkConference is a two-day event with more than 230 presenting companies and isattended by over 1,200 buy side investors. The 2006 conference had more than2,000 one-on-one meetings.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and marketsbiotechnology-based detection solutions to a diverse customer base, acrossmultiple industrial and human health markets. By applying its core competencyof creating custom antibodies to assay development, the Company producesunique, sophisticated diagnostic testing and reagent systems that areresponsive to customer diagnostic and information needs. Customers benefitwith quantifiable "return on investment" by